The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic

Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

(2009) D. Plachouras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models

(2009) R. V. Dudhani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity

(2009) Maura S. Oliveira et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy

Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections

(2009) Ayşe Erbay et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Stable Polymyxin B Susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug

(2009) A. P. Zavascki et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients

(2008) Alexandre P. Zavascki et al.   CLINICAL INFECTIOUS DISEASES

Intravenous colistimethate for multidrug-resistant Gram-negative bacteria

(2008) Alexandre P Zavascki et al.   LANCET INFECTIOUS DISEASES